Ivosidenib as IDH1 inhibitor and enasidenib as IDH2 inhibitor are approved by the FDA for monotherapy in patients with relapsed/refractory AML and a proven mutation in the respective enzyme inducing CR in approximately 20% of patients [61, 62]. Here, IDH2 is linked to acute myeloid leukemia.